ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2347

Drug Survival in Spondyloarthritis: Anti-IL17 Outperforms Anti-TNF in First Biologic Treatment

Thao Pham1, Raphaëlle Curmin2, BENOIT FLACHAIRE3, Florence Tubach2 and Corinne MICELI4, 1Assistance Publique-Hôpitaux de Marseille, Marseille, France, 2Cephepi, Sorbonne Université, INSERM, APHP, Paris, Paris, France, 3Aix Marseille University, Marseille, France, 4Université de Paris Cité, APHP, Paris, France

Meeting: ACR Convergence 2024

Keywords: Anti-TNF Drugs, Biologicals, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: SpA Including PsA – Treatment Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Drug survival rates serve as key indicators for assessing both the efficacy and safety of treatments in real life setting. Our aim was to compare the drug retention of first line biologics, anti-tumor necrosis factor (anti-TNF) therapies or anti-interleukin 17 (anti-IL17) therapies.

Methods: This retrospective cohort study, using data from the French National Health Data System (SNDS), included adult patients diagnosed with Spondyloarthritis (SpA), encompassing axial SpA (axSpA) and Psoriatic Arthritis (PsA), who initiated a first biologic, either anti-TNF or anti-IL17 agent, between January 1, 2015, and December 31, 2018. Follow-up extended until December 31, 2020. We choose to discontinue follow-up before the COVID-19 pandemic period, which could have had an impact on drug survival. Drug survival was described with Kaplan-Meier curves, and predictive factors were identified with a multivariable Cox model adjusted for age, gender, calendar initiation period, and potential indication modifiers such as multiple sclerosis, heart failure, psoriasis, and cancer.

Results: Of the 26,992 SpA patients initiating a first anti-TNF (n = 26,039) or a first anti-IL17 (n = 953), with a median age at initiation of 44.5 years ± 13.1 and 56.2% female, 25,553 (95.0%) had a diagnosis of axSpA, and 5,453 (20.2%) had PsA.

In the entire population, the median drug survival was 13.2 months (CI95 %: 12.8–13.6) for anti-TNF and 18.3 months (CI95 %: 16.2–21.1) for anti-IL17. The retention rates at 1 and 2 years were 52.3% (51.7-53.0) and 37.4% (36.9-38.0) with anti-TNF, compared to 60.6% (57.6-63.8) and 43.6% (40.5-46.9) with anti-IL17.

In the axSpA population, the median drug survival was 13.2 months (CI95 %: 12.9–13.7) for anti-TNF and 18.3 months (CI95 %: 19.0–21.5) for anti-IL17 (adjusted HR = 0.83 [0.76-0.91], p < 0.001). In the PsA population, the median drug survival was 12.0 months (CI95 %: 11.3–12.5) for anti-TNF and 19.7 months (CI95 %: 16.3–24.5) for anti-IL17 (adjusted HR = 0.73 [0.63-0.83], p < 0.001).

Conclusion: Our cohort study of 26,992 patients with SpA receiving a first biologic drug demonstrated better drug retention with anti-IL17 than with anti-TNF, regardless of SpA phenotype and independent of potential prescribing bias.

Supporting image 1


Disclosures: T. Pham: AbbVie, 6, Alfasigma, 6, Celltrion, 5, 6, Fresenius Kabi, 6, Galapagos, 6, Janssen, 5, 6, Lilly, 6, MSD, 6, Nordic Pharma, 6, Novartis, 6, Pfizer, 6, Sandoz, 5, 6, UCB, 6; R. Curmin: None; B. FLACHAIRE: None; F. Tubach: None; C. MICELI: None.

To cite this abstract in AMA style:

Pham T, Curmin R, FLACHAIRE B, Tubach F, MICELI C. Drug Survival in Spondyloarthritis: Anti-IL17 Outperforms Anti-TNF in First Biologic Treatment [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/drug-survival-in-spondyloarthritis-anti-il17-outperforms-anti-tnf-in-first-biologic-treatment/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/drug-survival-in-spondyloarthritis-anti-il17-outperforms-anti-tnf-in-first-biologic-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology